Jain PharmaBiotech, May 2012, Pages: 638
cell transplantation for cancerCancer drug/gene delivery by mesenchymal stemcellsCancer immunotherapy
Cytokines
Cancer vaccines
5T4 as a target for cancer immunotherapy
Anti-telomerase vaccine
BioPharm Reports (VennBio Ltd.), Jan 2011, Pages: 124
.2 The challenges of therapeuticallytargetingCancerStemCells
Figure 7.3 Potential diagnostic strategies for targetingCancerStemCells
List of Tables
Table 2.1 The global CSC drug developmentpipeline
Table 3
Axis Research Mind, May 2011, Pages: 692
AND ONCOLOGY THERAPEUTICSCANCERSTEMCELL SUGGESTION IN THYROID CANCER
FUTURE POTENTIALS
J. STEMCELLS TECHNOLOGY
AUTOMATED STEMCELL CULTURE WITH GREATER CONSISTENCY
RESTRICTIONS OBSERVED IN THE MANUAL
Bioseeker, June 2007, Pages: 172
. Drug targets and their associated antibodies have been analyzed according to:
- 34 Different molecular functions of target
- 13 Major signaling pathways
- Cancerstemcells
- Conjugated antibodies
BioPharm Reports (VennBio Ltd.), Jan 2009, Pages: 235
developmentpipeline and the potential of these cells in cancer diagnostics.
3.1 CancerStemCells
3.2 What are CancerStemCells?
3.3 Different Cancers
3.4 Drug Resistance
3.5 Drug Discovery
3.5.1 EGFR
Jain PharmaBiotech, May 2012, Pages: 658
Hematopoietic stemcells for targetedcancer gene therapy
Immunolipoplex for delivery of p53 gene
Nanomagnets for targetedcell-based cancer gene therapy
Nanoparticles for targeted site-specific delivery
GBI Research, Feb 2011, Pages: 100
- Advancement in Gene Therapy and StemCell Therapy will Drive the Market.” It provides key data, information and analysis on the main types of targetedtherapeutics and their key pipeline molecules. The report
Jain PharmaBiotech, May 2012, Pages: 485
.
Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo
Axis Research Mind, March 2011, Pages: 531
CONGESTIVE HEART FAILURE BIOHEART THERAPIES
STEMCELL MODULATOR PIPELINE WITH ACQUISITION OF FATE THERAPEUTICS WITH VERIO THERAPEUTICS
SRU BIOSYSTEMS ANNOUNCES INTRODUCTION OF BIND(R) SCANNER FOR PRIMARY
Business Insights, Feb 2007, Pages: 105
in the next 5 years?
-What impact will cancerstemscells, siRNA’s and vaccines have on drug development to 2011?
Top five reasons to order your copy today
-Gain a detailed insight into the evolution
Jain PharmaBiotech, May 2012, Pages: 873
as biomarker of efficacy of cancer gene therapy
Biomarkers of angiogenesis for developing antiangiogenic therapy
Biomarkers of response to antiangiogenic agents
Circulating endothelial cells as targets
GBI Research, Feb 2011, Pages: 209
Therapies and Gene Therapies
Summary
GBI Research’s new report, “Early Stage Drug Development in Disease Segments – Innovation Focuses on StemCell Therapies and Gene Therapies”, provides an in-depth
Spectra Intelligence, Nov 2006, Pages: 367
IN PRECLINICAL DEVELOPMENT
4.1 Strategic Development of Novel Anticancer Agents
4.2 Major Cancer Pathway Sources of Small Molecule TherapeuticTargets: PTEN/PI3K/Akt
4.3 RAS Activated Cell Proliferation Pathway
TriMark Publications, July 2007, Pages: 270
for Orthopedic Disease in Development 35
Table 2.8: Cellular Therapies in Orthopedics Trauma and Fracture Markets 35
Table 2.9: StemCell-based Therapeutics for Cardiac and Ischemic Diseases in Development 37
Jain PharmaBiotech, May 2012, Pages: 530
of chronic pain
Role of glia in neuropathic pain
Molecular and neurobiological techniques
Improved understanding of cancer pain
Advances in drug discovery and development for pain
Novel targets for drug
GlobalData, Aug 2011, Pages: 21
includes peptide based vaccine to targetcancerstemcells, cellular immunotherapies targetingcancer antigens, cancerstemcell antigens, and monoclonal antibodies to diagnose and treat several different
